Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JALYN | Waylis Therapeutics | N-022460 RX | 2010-06-14 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
dutasteride and tamsulosin hydrochloride | ANDA | 2024-11-28 |
flomax | New Drug Application | 2025-01-02 |
jalyn | New Drug Application | 2024-07-18 |
tamsulosin hydrochloride | ANDA | 2025-03-25 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Drug common name | Tamsulosin |
INN | tamsulosin |
Description | Tamsulosin is a 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide that has (R)-configuration. A specific alpha1 adrenoceptor antagonist used (generally as its hydrochloride salt, tamsulosin hydrochloride) in the treatment of prostatic hyperplasia, chronic prostatitis, urinary retention, and help with the passage of kidney stones. It has a role as an alpha-adrenergic antagonist and an antineoplastic agent. It is a conjugate base of a tamsulosin(1+). It is an enantiomer of an ent-tamsulosin. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1 |
PDB | — |
CAS-ID | 106133-20-4 |
RxCUI | — |
ChEMBL ID | CHEMBL836 |
ChEBI ID | 9398 |
PubChem CID | 129211 |
DrugBank | DB00706 |
UNII ID | G3P28OML5I (ChemIDplus, GSRS) |